HHummingbird Bioscience develops precision biotherapeutics for cancer and autoimmune diseases using a data-driven Rational Antibody Discovery platform. The platform combines biology, data analysis, and technology to engineer next-generation therapies and target biologically validated but previously undruggable targets. It advances drugs through biomarker-driven clinical trials, using measurable biomarkers to assess treatment effectiveness and guide development. The company differentiates itself by applying a systems biology approach and multi-omics data to design antibodies and therapies with higher specificity, aiming to improve clinical outcomes in patients who do not respond to current treatments. Its goal is to bring effective, targeted treatments to market that address unmet medical needs in oncology and autoimmunity.
Work here?Claim your company
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
Series C
Total Funding
$163.1M
Headquarters
Singapore, Singapore
Founded
2015
See people who can refer or advise you
Total Funding
$163.1M
Above
Industry Average
Funded Over
3 Rounds
Industry standards
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
Series C
Total Funding
$163.1M
Headquarters
Singapore, Singapore
Founded
2015
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs